Stabilis

Ursodesoxycholique acid



Stabilité des préparations

		5000 mg ® = ?	Inorpha® 100 mL Gomme xanthane 0,25% 250 mg	2-6°C		90				4498
		5000 mg ® = ?	Inorpha® 100 mL Gomme xanthane 0,25% 250 mg	20-24°C		60				4498
		3600 mg Actigal®	Glycérine Sirop simple >> 60 ml	4°C		35				2449
		3000 mg ® = ?	SyrSpend SF PH4® >> 150 ml	2-8°C	?	90				4177
		3000 mg Urso®	OraSweet SF® / sirop de fraise (1:1) >> 60	23-25°C		90				2410
		3000 mg Urso®	OraPlus® / OraSweet SF® (1:1) >> 60 ml	23-25°C		90				2410
		4000 mg Ursodiol®	Acésulfame potassique 400 mg Glycosides de stéviol 95% 400 mg Suspendit® 80 mL	25°C		181				4214
		8000 mg Ursodiol®	Acésulfame potassique 400 mg Glycosides de stéviol 95% 400 mg Suspendit® 80 mL	25°C		181				4214
		3000 mg Urso®	OraSweet SF® / sirop de fraise (1:1) >> 60	3-5°C		90				2410
		3000 mg Urso®	OraPlus® / OraSweet SF® (1:1) >> 60 ml	3-5°C		90				2410
		8000 mg Ursodiol®	Acésulfame potassique 400 mg Glycosides de stéviol 95% 400 mg Suspendit® 80 mL	5°C		181				4214
		4000 mg Ursodiol®	Acésulfame potassique 400 mg Glycosides de stéviol 95% 400 mg Suspendit® 80 mL	5°C		181				4214

?		1,5 g ® = ?	Glycérine 20 g Methylcellulose 1%	>> 100 mL	25°C		60			3782
?		1,5 g ® = ?	Glycérine 20 g Methylcellulose 1%	>> 100 mL	40°C		60			3782
?		1,5 g ® = ?	Glycérine 20 g Methylcellulose 1%	>> 100 mL	5°C		30			3782
PH= 4.4										

Bibliographie

	Type	Source
2410	Revue	Johnson CE, Streetman DD. Stability of oral suspensions of ursodiol made from tablets Am J Health-Syst Pharm 2002 ; 59: 361-363.
2449	Revue	Johnson CE, Nesbitt J. Stability of ursodiol in an extemporaneously compounded oral liquid Am J Health-Syst Pharm 1995 ; 52: 1798-1800.
3782	Revue	A. Santove?a, E. S?nchez-Negr?n, L. Charola, M. Llabr?s, J.B. Fari?a Study of quality and stability of ursodeoxycholic acid formulations for oral pediatric administration Int J Pharm 2014 , 477, 1-2 : 32-38.
4177	Revue	Polonini H, Loures da Silva S, Fernandes Brandao M.A, Bauters T, De Moerloose B, De Oliveira Ferreira A. Compatibility of Baclofen, Carvedilol, Hydrochlorothiazide, Mercaptopurine, Methadone Hydrochloride, Oseltamivir Phosphate, Phenobarbital, Propranolol Hydrochloride, Pyrazinamide, Sotalol Hydrochloride, Spironolactone, Tacrolimus Monohydrate, Ursodeoxycholic Acid, and Vancomycin Hydrochloride Oral Suspensions Compounded with SyrSpend SF PH4. Int J Pharm Compound 2018 ;22,6:516-526
4214	Revue	Pramar Y.V, Mandal T.K, Bostanian L.A, Nguyen A.TQ, Miller V, Morris T.C, Graves R.A. Stability of Compounded Ursodiol Suspensions in PCCA Base, SuspendIt. Int J Pharm Compound 2019 ;23,1:70-76
4498	Revue	Hausherr A, Roessle C, Pinet E, Vasseur V, Abarou T, Benakouche S, Bourdon O, Storme T. Development and validation of a new HPLC method for the analysis of a novel oral suspension formulation of 50 mg/mL ursodesoxycholic acid for newborns. Pharmaceutical Technology in Hospital Pharmacy 2020

Dictionnaire

	Divers
	Stabilité des préparations
	Origine
	Température
	Durée de stabilité
	Données conflictuelles
	Verre
	A l'abri de la lumière
	Gélules
	Non précisée
	Non précisé
	Dictionnaire

	Solution buvable
	Contenant
	Excipient
	Conservation
	Biosimilaire
	Bibliographie
	Poudre
	Jour
	Flacon plastique
	Comprimés
	Bibliographie